Article Sidebar

PDF
Date Published: 26/08/2022
Abstract Views: 201
Views PDF: 163
DOI: https://doi.org/10.51298/vmj.v517i2.3285
Issue
Vol. 517 No. 2 (2022)
Section
Các bài báo
How to Cite
Thị Thanh Thúy, . N. ., Huyền Nga, Đỗ ., Quang Trung, N., & Khánh Toàn, N. . (2022). SURVIVAL STUDY AND SOME FACTORS AFFECTING IN FIRST-LINE GEFITINIB TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER WITH EGFR MUTATION. Vietnam Medical Journal, 517(2). https://doi.org/10.51298/vmj.v517i2.3285

SURVIVAL STUDY AND SOME FACTORS AFFECTING IN FIRST-LINE GEFITINIB TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER WITH EGFR MUTATION

Nguyễn Thị Thanh Thúy1,, Đỗ Huyền Nga2, Nguyễn Quang Trung1, Nguyễn Khánh Toàn1
1 Nghe An Oncology Hospital
2 Vietnam National Cancer Hospital

Main Article Content

Abstract

Objective: To study the survival and some factors influencing on the survival in advanced non- small cell lung cancer patient with EGFR mutation used Gefitinib as the primary treatment. Subject and method: 69 non- small cell lung cancer patients used Gefitinib 250 mg per day until progressive disease or unacceptable toxicity. Results: Response rate was 85,5%; Disease control rate was 94,2%; Progression free survival time 12,6 ± 1,1 months; overall survival 21,8 ± 2,5 months. The patient's overall condition and EGFR gene mutation significantly related the Progression- free survival time.

Article Details

Keywords

Non- small cell lung cancer, Gefitinib

References

1. GLOBOCAN. International agency for research on cancer. 2020.
2. Wakelee H, Kelly K, Edelman MJ. 50 Years of Progress in the Systemic Therapy of Non–Small Cell Lung Cancer. American Society of Clinical Oncology Educational Book. 2014;(34):177-189. doi:10.14694/EdBook_AM.2014.34.177
3. Schiller JH, Harrington D, Belani CP, et al. Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer. New England Journal of Medicine. 2002;346(2):92-98. doi:10.1056/NEJMoa011954
4. Mok TS, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009 Sep 3;361(10):947-57. doi: 10.1056/ NEJMoa 0810699. Epub 2009 Aug 19. PMID: 19692680.
5. Nguyễn Văn Cao. Đánh giá kết quả điều trị Gefitinib bước 1 ung thư phổi không tế bào nhỏ giai đoạn IV có đột biến EGFR tại Bệnh viện K. Tạp chí Ung thư học Việt Nam. Published online 2019:224-229.
6. Ohe Y, Imamura F, Nogami N, et al. Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset. Jpn J Clin Oncol. 2019;49(1):29-36. doi:10.1093/jjco/hyy179
7. Jiang H, Zhu M, Li Y, Li Q. Association between EGFR exon 19 or exon 21 mutations and survival rates after first-line EGFR-TKI treatment in patients with non-small cell lung cancer. Mol Clin Oncol. 2019;11(3):301-308. doi:10.3892/mco.2019.1881
8. Đỗ Thị Phương Chung, Nguyễn Lam Hòa, Trần Văn Thuấn (2015). Đánh giá bước đầu hiệu quả thuốc Gefitinib trong điều trị bệnh nhân ung thư phổi không tế bào nhỏ tái phát, di căn. Tạp chí Ung thư học Việt Nam, Số 4.:200-203.